

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed		1		
Dosing Accident		1		
Moribund Sacrifice	7	8	7	8
Natural Death	5	4	1	1
Survivors				
Terminal Sacrifice	38	36	42	41
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Liver				1 (2%)
Gallbladder	(49)	(49)	(50)	(50)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Carcinoma				1 (2%)
Sarcoma, Metastatic, Mesentery		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Hemangioma			2 (4%)	
Hemangiosarcoma		1 (2%)		
Hepatoblastoma	1 (2%)	3 (6%)	5 (10%)	2 (4%)
Hepatoblastoma, Multiple			2 (4%)	
Hepatocellular Adenoma	16 (32%)	12 (24%)	8 (16%)	10 (20%)
Hepatocellular Adenoma, Multiple	6 (12%)	19 (38%)	27 (54%)	18 (36%)
Hepatocellular Carcinoma	11 (22%)	9 (18%)	16 (32%)	12 (24%)
Hepatocellular Carcinoma, Multiple	2 (4%)	2 (4%)	2 (4%)	3 (6%)
Hepatocholangiocarcinoma				1 (2%)
Hepatocholangiocarcinoma, Multiple				1 (2%)
Hepatocholangioma				1 (2%)
Sarcoma, Metastatic, Mesentery		1 (2%)		
Mesentery	(4)	(2)	(3)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Hepatoblastoma, Metastatic, Liver			1 (33%)	
Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (25%)			
Sarcoma		1 (50%)		
Pancreas	(50)	(50)	(50)	(50)
Hepatoblastoma, Metastatic, Liver			1 (2%)	
Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Sarcoma, Metastatic, Mesentery		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma	1 (2%)			
Squamous Cell Papilloma		2 (4%)		1 (2%)
Squamous Cell Papilloma, Multiple				1 (2%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Tooth	(37)	(37)	(35)	(20)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(50)	(50)	(50)
Aorta, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Heart				1 (2%)
Hemangiosarcoma, Metastatic, Spleen			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Hepatoblastoma, Metastatic, Liver			1 (2%)	
Sarcoma, Metastatic, Mesentery		1 (2%)		
Subcapsular, Adenoma	1 (2%)	3 (6%)	3 (6%)	
Adrenal Medulla	(50)	(50)	(50)	(50)
Pheochromocytoma Benign	1 (2%)	1 (2%)	1 (2%)	
Pheochromocytoma Malignant				1 (2%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Pituitary Gland	(50)	(50)	(50)	(50)
Thyroid Gland	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Follicular Cell, Carcinoma		1 (2%)	2 (4%)	
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Coagulating Gland	(1)	(1)	(0)	(1)
Sarcoma, Metastatic, Mesentery		1 (100%)		
Epididymis	(50)	(50)	(50)	(50)
Hemangiosarcoma, Metastatic, Spleen				1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Sarcoma, Metastatic, Mesentery		1 (2%)		
Preputial Gland	(50)	(50)	(50)	(50)
Prostate	(50)	(50)	(50)	(50)
Sarcoma, Metastatic, Mesentery		1 (2%)		
Seminal Vesicle	(50)	(50)	(50)	(50)
Sarcoma, Metastatic, Mesentery		1 (2%)		
Testes	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma			1 (2%)	1 (2%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma			1 (2%)	
Hemangiosarcoma, Metastatic, Spleen	1 (2%)			1 (2%)
Hemangiosarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Lymph Node	(1)	(3)	(0)	(2)
Mediastinal, Hepatocholangiocarcinoma, Metastatic, Liver				1 (50%)
Mediastinal, Sarcoma, Metastatic, Mesentery		1 (33%)		
Lymph Node, Mandibular	(50)	(50)	(50)	(50)
Lymph Node, Mesenteric	(47)	(49)	(45)	(44)
Spleen	(50)	(50)	(50)	(50)
Hemangiosarcoma	2 (4%)	2 (4%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Thymus Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	(49)	(46)	(45)	(42) 1 (2%)
INTEGUMENTARY SYSTEM				
Skin Hemangiosarcoma Sarcoma	(50)	(50) 1 (2%) 1 (2%)	(50)	(50)
MUSCULOSKELETAL SYSTEM				
Bone Skeletal Muscle Rhabdomyosarcoma	(50) (1) 1 (100%)	(50) (0)	(50) (0)	(50) (0)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
RESPIRATORY SYSTEM				
Lung Alveolar/Bronchiolar Adenoma Alveolar/Bronchiolar Carcinoma Alveolar/Bronchiolar Carcinoma, Multiple Carcinoma, Metastatic, Thyroid Gland Hemangiosarcoma, Metastatic, Skin Hepatoblastoma, Metastatic, Liver Hepatocellular Carcinoma, Metastatic, Liver Hepatocholangiocarcinoma, Metastatic, Liver Rhabdomyosarcoma, Metastatic, Skeletal Muscle Sarcoma, Metastatic, Skin Serosa, Hepatocholangiocarcinoma, Metastatic, Liver	(50) 6 (12%) 3 (6%)	(50) 5 (10%) 3 (6%) 1 (2%) 1 (2%) 4 (8%)	(50) 6 (12%) 4 (8%) 1 (2%) 1 (2%) 2 (4%)	(50) 5 (10%) 3 (6%) 5 (10%) 1 (2%) 1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Nose Osteoma	(50)	(50)	(50)	(50) 1 (2%)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Harderian Gland	(50)	(50)	(50)	(50)
Adenoma	6 (12%)	4 (8%)	7 (14%)	7 (14%)
Adenoma, Multiple			1 (2%)	
Carcinoma	1 (2%)			
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Thyroid Gland			1 (2%)	
Hepatoblastoma, Metastatic, Liver			1 (2%)	
Renal Tubule, Adenoma		1 (2%)		
Urethra	(0)	(0)	(1)	(0)
Transitional Epithelium, Carcinoma			1 (100%)	
Urinary Bladder	(50)	(50)	(50)	(50)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma		2 (4%)	1 (2%)	
Lymphoma Malignant	1 (2%)	1 (2%)		2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
------------------	---------	------------	----------	-----------

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	38	43	44	43
Total Primary Neoplasms	60	75	91	72
Total Animals with Benign Neoplasms	30	35	37	37
Total Benign Neoplasms	36	47	56	45
Total Animals with Malignant Neoplasms	19	24	28	22
Total Malignant Neoplasms	24	28	35	27
Total Animals with Metastatic Neoplasms	4	7	4	7
Total Metastatic Neoplasms	7	15	10	14
Total Animals with Malignant Neoplasms Uncertain Primary Site	1			
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident				1
Moribund Sacrifice	9	3	5	9
Natural Death	5	6	7	3
Survivors				
Terminal Sacrifice	35	41	38	37
Animals Examined Microscopically	49	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(49)	(50)	(50)	(50)
Gallbladder	(48)	(50)	(50)	(50)
Osteosarcoma, Metastatic, Bone			1 (2%)	
Intestine Large, Cecum	(49)	(50)	(50)	(50)
Leiomyoma		1 (2%)		
Intestine Large, Colon	(49)	(50)	(50)	(50)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Intestine Large, Rectum	(49)	(50)	(50)	(50)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Intestine Small, Duodenum	(49)	(50)	(50)	(50)
Osteosarcoma, Metastatic, Bone			1 (2%)	
Intestine Small, Ileum	(49)	(50)	(50)	(50)
Intestine Small, Jejunum	(49)	(50)	(50)	(50)
Liver	(49)	(50)	(50)	(50)
Hepatoblastoma		1 (2%)	2 (4%)	1 (2%)
Hepatoblastoma, Multiple				1 (2%)
Hepatocellular Adenoma	7 (14%)	7 (14%)	10 (20%)	15 (30%)
Hepatocellular Adenoma, Multiple	6 (12%)	8 (16%)	3 (6%)	12 (24%)
Hepatocellular Carcinoma	5 (10%)	1 (2%)	3 (6%)	8 (16%)
Hepatocellular Carcinoma, Multiple			1 (2%)	
Hepatocholangiocarcinoma				1 (2%)
Osteosarcoma, Metastatic, Bone			1 (2%)	
Sarcoma, Metastatic, Skin		1 (2%)		
Mesentery	(6)	(12)	(11)	(2)
Osteosarcoma, Metastatic, Bone			1 (9%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Sarcoma, Metastatic, Skeletal Muscle				1 (50%)
Sarcoma, Metastatic, Skin		1 (8%)		
Pancreas	(49)	(50)	(50)	(50)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Sarcoma, Metastatic, Skin		1 (2%)		
Salivary Glands	(49)	(50)	(49)	(50)
Stomach, Forestomach	(49)	(50)	(50)	(50)
Squamous Cell Papilloma	2 (4%)	4 (8%)	1 (2%)	1 (2%)
Squamous Cell Papilloma, Multiple			1 (2%)	
Stomach, Glandular	(49)	(50)	(50)	(50)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Tongue	(0)	(0)	(0)	(1)
Squamous Cell Carcinoma				1 (100%)
Tooth	(3)	(1)	(2)	(1)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(49)	(50)	(50)	(50)
Heart	(49)	(50)	(50)	(50)
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(50)	(50)	(50)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Subcapsular, Adenoma	1 (2%)			
Adrenal Medulla	(49)	(50)	(50)	(50)
Pheochromocytoma Benign	1 (2%)	2 (4%)		1 (2%)
Islets, Pancreatic	(49)	(50)	(50)	(50)
Parathyroid Gland	(45)	(47)	(39)	(39)
Pituitary Gland	(49)	(50)	(49)	(49)
Pars Distalis, Adenoma	2 (4%)	2 (4%)		
Thyroid Gland	(49)	(50)	(49)	(50)
Follicular Cell, Adenoma	1 (2%)	1 (2%)		
Follicular Cell, Carcinoma	1 (2%)			
GENERAL BODY SYSTEM				
None				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
GENITAL SYSTEM				
Clitoral Gland	(47)	(50)	(49)	(49)
Ovary	(49)	(49)	(50)	(50)
Cystadenocarcinoma		1 (2%)		
Cystadenoma	1 (2%)	2 (4%)		2 (4%)
Granulosa Cell Tumor Benign	1 (2%)			
Granulosa Cell Tumor Malignant				1 (2%)
Hemangioma	1 (2%)		1 (2%)	
Hemangiosarcoma	1 (2%)			
Luteoma		1 (2%)		
Osteosarcoma, Metastatic, Bone			1 (2%)	
Teratoma Benign			1 (2%)	
Uterus	(49)	(49)	(50)	(50)
Polyp Stromal			3 (6%)	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(49)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)		1 (2%)	1 (2%)
Lymph Node	(1)	(2)	(5)	(2)
Inguinal, Sarcoma, Metastatic, Skin			1 (20%)	
Mediastinal, Osteosarcoma, Metastatic, Bone			1 (20%)	
Mediastinal, Schwannoma Malignant, Metastatic, Skin	1 (100%)			
Lymph Node, Mandibular	(49)	(50)	(49)	(50)
Lymph Node, Mesenteric	(47)	(49)	(50)	(49)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Spleen	(49)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			1 (2%)
Thymus	(48)	(49)	(49)	(46)
INTEGUMENTARY SYSTEM				
Mammary Gland	(49)	(50)	(50)	(50)
Adenoacanthoma	1 (2%)			
Carcinoma	1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Skin	(49)	(50)	(50)	(50)
Fibrosarcoma	1 (2%)			1 (2%)
Fibrous Histiocytoma	1 (2%)			
Sarcoma		2 (4%)	1 (2%)	1 (2%)
Schwannoma Malignant	1 (2%)		1 (2%)	
Schwannoma Malignant, Multiple	1 (2%)	1 (2%)		
MUSCULOSKELETAL SYSTEM				
Bone	(49)	(50)	(50)	(50)
Osteoma			1 (2%)	
Osteosarcoma			1 (2%)	1 (2%)
Skeletal Muscle	(0)	(0)	(1)	(1)
Rhabdomyosarcoma			1 (100%)	
Sarcoma				1 (100%)
NERVOUS SYSTEM				
Brain	(49)	(50)	(50)	(50)
RESPIRATORY SYSTEM				
Lung	(49)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	5 (10%)	2 (4%)	3 (6%)
Alveolar/Bronchiolar Carcinoma	2 (4%)	1 (2%)	1 (2%)	3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			2 (4%)
Osteosarcoma, Metastatic, Bone			1 (2%)	
Sarcoma, Metastatic, Skin		1 (2%)	1 (2%)	1 (2%)
Schwannoma Malignant, Metastatic, Skin	1 (2%)		1 (2%)	
Nose	(49)	(50)	(50)	(50)
Osteoma			1 (2%)	
SPECIAL SENSES SYSTEM				
Eye	(49)	(50)	(49)	(50)
Harderian Gland	(49)	(50)	(49)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Adenoma	7 (14%)	6 (12%)	4 (8%)	6 (12%)
Carcinoma	1 (2%)		2 (4%)	2 (4%)
URINARY SYSTEM				
Kidney	(49)	(50)	(50)	(50)
Osteosarcoma, Metastatic, Bone			1 (2%)	
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Renal Tubule, Adenoma	1 (2%)			
Urinary Bladder	(49)	(49)	(50)	(50)
SYSTEMIC LESIONS				
Multiple Organs	*(49)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	3 (6%)	1 (2%)		3 (6%)
Leukemia Granulocytic			1 (2%)	
Lymphoma Malignant	6 (12%)	2 (4%)	4 (8%)	6 (12%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Pulegone

Time Report Requested: 09:18:35

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: 04/15/03 / 04/14/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
--------------------	---------	------------	----------	-----------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	40	26	34	41
Total Primary Neoplasms	59	50	48	73
Total Animals with Benign Neoplasms	27	22	24	32
Total Benign Neoplasms	32	39	28	40
Total Animals with Malignant Neoplasms	20	11	17	23
Total Malignant Neoplasms	27	11	20	33
Total Animals with Metastatic Neoplasms	2	1	3	3
Total Metastatic Neoplasms	3	4	11	11
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors